| Literature DB >> 35566663 |
Gregor Paul1,2, Laurin Ochs3, Christopher Hohmann3, Stephan Baldus3, Guido Michels4, Charlotte Meyer-Schwickerath1, Gerd Fätkenheuer1,5, Navid Mader6, Thorsten Wahlers6, Carolyn Weber6, Norma Jung1.
Abstract
Staphylococcus aureus (SA) and Streptococcus species (SS) show different clinical manifestations in infective endocarditis (IE), but the impact on the complexity of surgical treatment remains unclear. All patients with surgically treated IE due to SA or SS between July 2013 and December 2016 were extracted from a prospectively collected, single-center registry. Data on patient characteristics, surgical procedures, and postprocedural outcomes were collected. SA-IE was more common with prosthetic valves (26.3% vs. 7.3%, p = 0.04), cardiac devices (14.3% vs. 0%, p = 0.03), previous cardiac surgery (28.6% vs. 9.8%, p = 0.03), intravenous drug abuse (14.3% vs. 0%, p = 0.03), and embolic events (57.1% vs. 26.8%, p = 0.007). Preoperative CRP was significantly higher in SA-IE (median 96.1 mg/L vs. 42.4 mg/L, p = 0.002). Otherwise, SS-IE affected more cusps/leaflets (mean 2.4 vs. 1.8, p = 0.03) and led to more valve dysfunction (83.8% vs. 54.3%, p = 0.007). Surgery times did not differ between the groups, though patients with SA spent more time in the intensive care unit (median 7 vs. 4.5 days, p = 0.04). Hospital mortality did not differ, but patients with SA-IE had unfavorable long-term survival (p = 0.001). Future studies need to be larger and focus on the mechanism behind the reduced long-term survival to mitigate the deleterious effect of SA in surgically treated patients with IE.Entities:
Keywords: endocarditis; staphylococcus aureus; streptococcus; surgery; survival
Year: 2022 PMID: 35566663 PMCID: PMC9104614 DOI: 10.3390/jcm11092538
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Figure 1Flow diagram showing study population selection.
Demographics and clinical characteristics of patients with infective endocarditis treated surgically and caused by Staphylococcus aureus or Streptococcus species.
|
| |||
| Age, y; median (IQR) | 57 (45.8–72.3) | 58 (50–70.5) | 0.89 |
| Male sex | 25/42 (59.5) | 30/40 (73.2) | 0.19 |
| Diabetes | 11/42 (26.2) | 4/40 (10) | 0.06 |
| COPD | 5/42 (11.9) | 1/40 (2.5) | 0.1 |
| Carcinoma | 1/42 (2.4) | 1/40 (2.5) | 0.97 |
| IVDU | 6/42 (14.3) | 0/40 |
|
| Chronic renal failure | 13/42 (31) | 10/41 (24.4) | 0.63 |
| Previous dialysis | 7/41 (17.1) | 2/34 (5.9) | 0.17 |
| New renal failure before surgery | 10/42 (23.8) | 6/41 (14.6) | 0.29 |
| Previous endocarditis | 2/41 (4.9) | 0/34 | 0.19 |
| Previous cardiac surgery | 12/42 (28.6) | 4/41 (9.8) |
|
| Community-acquired IE | 38/41 (92.7) | 41/41 (100) | 0.24 |
|
| |||
| Vegetation size, cm; mean (SD) | 1.4 (0.95) | 1.56 (0.64) | 0.61 |
| Prosthetic | 11/42 (26.2) | 3/41 (7.3) |
|
| Cardiac device (PM, ICD, or CRT) | 6/42 (14.3) | 0/40 (0) |
|
| Aortic | 24/42 (57.1) | 27/41 (65.9) | 0.26 |
| Mitral | 21/42 (50) | 19/41 (46.3) | 1 |
| Tricuspid | 5/42 (11.9) | 0/41 (0) |
|
| Pulmonary | 0/42 (0) | 3/41 (7.3) | 0.07 |
| Echocardiographic abscess | 9/42 (21.4) | 5/41 (12.2) | 0.38 |
| Intraoperative abscess | 17/42 (40.5) | 10/41 (24.4) | 0.16 |
|
| |||
|
| 24/42 (57.1) | 11/41 (26.8) |
|
| No embolism | 18/42 (42.9) | 31/41 (75.6) | 0.002 |
| Cerebral | 17/42 (40.5) | 8/41 (19.5) | 0.04 |
| Spleen | 6/42 (14.3) | 1/41 (2.4) | 0.05 |
| Other | 1/42 (2.4) | 1/41 (2.4) | 1 |
| Extracardiac focus (e.g., osteomyelitis) | 10/40 (25) | 3/39 (7.7) | 0.07 |
|
| |||
| Preoperative WBC, T/µL; median (IQR) | 10.6 (7.9–15) | 10.3 (6.8–13.6) | 0.67 |
| Preoperative CRP, mg/L; median (IQR) | 96.1 (32.8–177.3) | 42.4 (11.25–76.2) |
|
IQR, interquartile range; COPD, chronic obstructive pulmonary disease; IVDU, intravenous drug user; IE, infective endocarditis; PM, pacemaker; ICD, implantable cardioverter-defibrillator; CRT, cardiac resynchronization therapy; WBC, white blood cell count; CRP, C-reactive protein. Bold indicates a p-value below 0.05.
Surgical procedures and postoperative outcome in patients with Staphylococcus aureus or Streptococcus spp. endocarditis.
| Euroscore II, %; mean (SD) | 8.5 (3.4) | 7.9 (3.1) | 0.5 |
|
| 0.77 | ||
| Elective | 16/42 (38.1) | 16/41 (39) | |
| Urgent | 19/42 (45.2) | 16/41 (39) | |
| Emergency | 7/42 (16.7) | 9/41 (22) | |
|
|
| ||
| Embolism | 13/35 (37.1) | 5/37 (13.5) | 0.02 |
| Valvular dysfunction | 19/35 (54.3) | 31/37 (83.8) | 0.007 |
| Vegetation size | 0/35 | 1/37 (2.7) | 0.33 |
| Abscess | 2/35 (5.7) | 0/35 | 0.14 |
| Persistent bacteremia | 1/35 (2.9) | 0/35 | 0.3 |
|
| 1 | ||
| Biological | 20/42 (47.6) | 19/41 (46.3) | |
| Prosthetic | 21/42 (50) | 20/41 (48.8) | |
| Other | 1/42 (2.4) | 2/41 (4.9) | |
|
| 0.89 | ||
| No additional procedure | 23/42 (54.8) | 25/49 (62.5) | |
| Endocarditis related | 10/42 (23.8) | 5/40 (12.5) | |
| Atrial appendage closure | 2/42 (4.8) | 3/40 (7.5) | |
| Patent foramen ovale | 1/42 (2.4) | 1/40 (2.5) | |
| Coronary artery graft bypass | 4/42 (9.5) | 4/40 (10) | |
| Reconstruction mitral or tricuspid valve | 2/42 (4.8) | 2/40 (5) | |
| Days antibiotics before surgery, days; mean (SD) | 18.1 (17.7) | 16.3 (17.2) | 0.46 |
| Days antibiotics after surgery, days; mean (SD) | 38.6 (15.4) | 24.9 (13) |
|
|
|
| ||
| Positive | 21/42 (50) | 11/41 (26.8) | |
| Negative | 21/42 (50) | 28/41 (63.3) | |
| Not performed | 0 | 2/41 (4.9) | |
|
|
| ||
| Positive | 9/42 (21.4) | 28/41 (68.3) | |
| Negative | 7/42 (16.7) | 7/41 (17.1) | |
| Not performed | 26/42 (61.9) | 6/41 (14.6) | |
| Operation time, minutes; median (IQR) | 204 (148.5–256) | 180 (154.25–216.75) | 0.22 |
| Bypass time, minutes; mean (SD) | 114.5 (80.8–160) | 107 (83–124) | 0.39 |
| Aortic clamp time, minutes, minutes; mean (SD) | 80.5 (48–109.5) | 71 (52.5–90.75) | 0.68 |
| Reperfusion time, minutes, minutes; mean (SD) | 25 (20–36) | 23.5 (18–35) | 0.44 |
| Invasive disease | 14/42 (33.3) | 9/41 (22) | 0.33 |
| Cusps/leaflets affected, N; mean (SD) | 1.8 (1.16) | 2.4 (1.16) |
|
| Postoperative pacemaker | 4/42 (9.8) | 3/34 (8.8) | 1 |
| Red blood packs, N; mean (SD) | 3 (0.5–4.5) | 2 (0–4) | 0.22 |
| Fresh frozen plasma, N; median (IQR) | 0 (0–4) | 0 (0–3.5) | 0.42 |
| Reoperation | 5/42 (11.9) | 1/41 (2.4) | 0.2 |
| Postoperative renal failure | 12/42 (28.6) | 8/41 (19.5) | 0.44 |
| Stroke/intracerebral bleeding after surgery | 4/40 (10) | 4/34 (11.8) | 1 |
| Ventilation hours, hours; median (IQR) | 48 (13.2–225.9) | 15.7 (10.5–80.9) | 0.07 |
| Days on intensive care, days; median (IQR) | 7 (2–12) | 4.5 (1.8–8.3) |
|
| Inhospital mortality | 5/41 (12.2) | 2/34 (5.9) | 0.45 |
SD, standard deviation; rRNA, ribosomal RNA; PCR, polymerase chain reaction; IQR, interquartile range. Bold indicates a p-value below 0.05.
Figure 2Cox proportional hazard regression showing impaired one-year survival in patients with surgically treated Staphylococcus aureus endocarditis compared to Streptococcus spp.